Clinical Trials
27 trialsNCT06161519 2026-05-13
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT06607692 2026-04-14
LUPARPED
Fundación de investigación HM
Phase 1/2 Recruiting
NCT05278208 2026-04-13
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Nationwide Children's Hospital
Phase 1/2 Recruiting
NCT02650401 2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT06639607 2026-03-10
PRiME II
Washington University School of Medicine
Phase 1/2 Not yet recruiting
NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
NCT07346157 2026-01-16
PNOC044
University of California, San Francisco
Phase 1/2 Not yet recruiting
NCT03904862 2025-10-30
Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery
Pediatric Brain Tumor Consortium
Phase 1/2 Terminated
NCT04758533 2024-12-27
AloCELYVIR
Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Phase 1/2 Active not recruiting
NCT01483820 2024-08-06
Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma
Milton S. Hershey Medical Center
Phase 1/2 Terminated
NCT06485908 2024-07-03
MEPENDAX
Assistance Publique Hopitaux De Marseille
Phase 1/2 Not yet recruiting
NCT04167618 2023-10-06
177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma
Y-mAbs Therapeutics
Phase 1/2 Terminated
NCT02095132 2023-09-26
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00788125 2023-07-14
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
City of Hope Medical Center
Phase 1/2 Terminated
NCT04730349 2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT00983398 2021-10-26
Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors
OHSU Knight Cancer Institute
Phase 1/2 Unknown
NCT01619865 2021-07-27
GA-68
University of Iowa
Phase 1/2 Completed
NCT01614132 2020-03-31
NOA-07
University of Regensburg
Phase 1/2 Completed
NCT01601184 2019-05-21
Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway
Centre Leon Berard
Phase 1/2 Terminated
NCT01977677 2018-10-23
Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
Stanford University
Phase 1/2 Completed
NCT02332889 2018-05-04
Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs
University of Louisville
Phase 1/2 Terminated
NCT01125800 2017-03-20
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
Novartis
Phase 1/2 Completed
NCT00003461 2014-08-21
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors
Duke University
Phase 1/2 Completed
NCT00002752 2014-07-16
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers
Duke University
Phase 1/2 Completed
NCT00095940 2014-05-23
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00005952 2013-06-20
Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors
Duke University
Phase 1/2 Completed
NCT00003478 2013-02-20
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain Tumors
Duke University
Phase 1/2 Completed